What does this approval mean for India?

For India, this is a great start to the new year! SII had applied for emergency use authorisation to India's drug regulator earlier this month. SII had submitted additional data required by the Drug Controller General of India (DCGI) for determining the safety and immunogenicity of its COVID-19 vaccine candidate.

How does this vaccine work?

The Oxford-AstraZeneca vaccine is based on a common cold virus found in chimpanzees. Scientists have tweaked this virus to carry genetic material that contains instructions for the spike protein of the novel coronavirus. Once in, they start producing the coronavirus' spike proteins, forcing our body to mount an immune response via both neutralising antibodies and killer T cells, that squash the infected cells.

The initial results published by Oxford-Astra-Zeneca showed that the vaccine was 62.1 percent efficacious in participants who received two standard doses, while it had 90 percent efficacy in participants who received a low dose followed by a standard dose. The findings were that there was 70 percent overall efficacy.

How many doses do you need to take?

Oxford vaccine was given in two different dosages: One set received a ‘low’ shot as the first dose and a ‘high’ shot as the second dose. The second set received ‘high’ doses both times. He says it’s surprising that the low dose produced better efficacy of 90 percent than a high dose that received an efficacy of 62 percent.

According to data from The Lancet, 21 days after the first dose - but it is not clear in which trial from which country - there were “ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death.” There were also 74 341 person-months of safety follow-up after the first dose (median 3.4 months) and 29,097 person-months of follow-up after two doses (median 2.0). 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Out of these, three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. One case of the neurological disorder transverse myelitis may be linked to the shot, as per The Lancet.

COVID-19 Vaccines from 16 January: Everything You Need to Know About the Oxford-AstraZeneca Vaccine

India is set to kick-off its vaccination drive from 16 January after the COVID-19 vaccine developed by Oxford University and pharma major AstraZeneca was one of the two vaccines to receive emergency use approval in India.

The Oxford vaccine can be stored in a standard fridge unlike the extreme cold storage requirements (-70 degree C) of the Pfizer-BioNtech candidate.

In India, the vaccine is also being produced under the name 'Covishield' by the Serum Institute of India (SII). It has been developed at SII's laboratory in Pune with a master seed from Oxford University/AstraZeneca.

Here’s a rundown of everything you need to know about the vaccine.

Read Latest News and Breaking News at The Quint, browse for more from news and india

Topics: coronavirus vaccine COVID-19 FAQ Coronavirus 2019 vaccine

Published: 03 Jan 2021, 12:00 PM IST

BECOME A MEMBER

Oxford-AstraZeneca: How Efficient Is It? What’s the Dosage Needed?

Oxford vaccine: What do we know about the Oxford-AstraZeneca vaccine so far? How does it work? Find out here.

Read Latest News and Breaking News at The Quint, browse for more from news and india

Topics: coronavirus vaccine COVID-19 FAQ Coronavirus 2019 vaccine